| Q64866394 | Q64866394 |
| Q33941381 | 1H-MRS at 4 tesla in minimally treated early schizophrenia |
| Q41664217 | 5-HT2 and D2 dopamine receptor occupancy in the living human brain. A PET study with risperidone |
| Q48350364 | A 52-week open-label study of the safety and tolerability of paliperidone palmitate in patients with schizophrenia. |
| Q47617662 | A 6-Month Prospective Trial of a Personalized Behavioral Intervention + Long-Acting Injectable Antipsychotic in Individuals With Schizophrenia at Risk of Treatment Nonadherence and Homelessness |
| Q36489406 | A 6-week, double-blind, placebo- and haloperidol-controlled, phase II study of lurasidone in patients with acute schizophrenia |
| Q48381074 | A 6-week, randomized, multicentre, open-label study comparing efficacy and tolerability of amisulpride at a starting dose of 400 mg/day versus 800 mg/day in patients with acute exacerbations of schizophrenia |
| Q35683860 | A 6-year open-label study of the efficacy and safety of olanzapine long-acting injection in patients with schizophrenia: a post hoc analysis based on the European label recommendation |
| Q34770351 | A Double-Blind, Placebo-Controlled Comparator Study of LY2140023 monohydrate in patients with schizophrenia |
| Q44659879 | A Double-Blind, Randomized, Placebo-Controlled Trial of Olanzapine in the Prevention of Psychotic Relapse |
| Q64238308 | A Long-Term, Open-Label Study to Evaluate the Safety and Tolerability of Brexpiprazole as Adjunctive Therapy in Adults With Major Depressive Disorder |
| Q71710528 | A PET study of D2 and 5-HT2 receptor occupancy induced by risperidone in poor metabolizers of debrisoquin and risperidone |
| Q47701023 | A Randomized Clinical Trial of Oxytocin or Galantamine for the Treatment of Negative Symptoms and Cognitive Impairments in People With Schizophrenia |
| Q36148557 | A Randomized Comparison of Aripiprazole and Risperidone for the Acute Treatment of First-Episode Schizophrenia and Related Disorders: 3-Month Outcomes |
| Q39841319 | A Randomized, Double-Blind Comparison of Risperidone Versus Low-Dose Risperidone Plus Low-Dose Haloperidol in Treating Schizophrenia |
| Q37299884 | A Randomized, Double-blind Study of the Efficacy and Tolerability of Extended Release Quetiapine Fumarate (Quetiapine XR) Monotherapy in Patients with Major Depressive Disorder |
| Q37299931 | A Randomized, Placebo-Controlled Pilot Study of Quetiapine-XR Monotherapy or Adjunctive Therapy to Antidepressant in Acute Major Depressive Disorder with Current Generalized Anxiety Disorder |
| Q37584106 | A case of paroxetine-induced akathisia and a review of SSRI-induced akathisia |
| Q36972466 | A case study of SMART attributes: a qualitative assessment of generalizability, retention rate, and trial quality |
| Q42678187 | A comparison of the efficacy and safety of olanzapine and risperidone in the treatment of elderly patients with schizophrenia: an open study of six months duration. |
| Q44515968 | A comparison of the efficacy and safety of olanzapine versus haloperidol during transition from intramuscular to oral therapy |
| Q36062173 | A controlled trial of quetiapine XR coadministration treatment of SSRI-resistant panic disorder. |
| Q34660425 | A controlled, evidence-based trial of paliperidone palmitate, a long-acting injectable antipsychotic, in schizophrenia |
| Q44790997 | A cross-validation study on the relationship between central D2 receptor occupancy and serum perphenazine concentration |
| Q30667146 | A current review of olanzapine's safety in the geriatric patient: from pre-clinical pharmacology to clinical data |
| Q64916852 | A customized adherence enhancement program combined with long-acting injectable antipsychotic medication (CAE-L) for poorly adherent patients with chronic psychotic disorder in Tanzania: A pilot study methodological report. |
| Q43832862 | A dose-ranging exploratory study of the effects of ethyl-eicosapentaenoate in patients with persistent schizophrenic symptoms |
| Q43827150 | A double-blind randomised comparison of risperidone and haloperidol in the treatment of behavioural and psychological symptoms in Chinese dementia patients |
| Q24624661 | A double-blind randomized controlled trial of olanzapine plus sertraline vs olanzapine plus placebo for psychotic depression: the study of pharmacotherapy of psychotic depression (STOP-PD) |
| Q51097389 | A double-blind, controlled comparison of the novel antipsychotic olanzapine versus haloperidol or placebo on anxious and depressive symptoms accompanying schizophrenia. |
| Q44393739 | A double-blind, placebo-controlled trial of sertraline for depressive symptoms in patients with stable, chronic schizophrenia |
| Q30422068 | A double-blind, placebo-controlled trial to assess the efficacy of quetiapine fumarate XR in very heavy-drinking alcohol-dependent patients |
| Q36475355 | A double-blind, placebo-controlled, randomized withdrawal study of lurasidone for the maintenance of efficacy in patients with schizophrenia |
| Q50132603 | A long-Term, Open-Label Study to Evaluate the Safety and Tolerability of Brexpiprazole as Maintenance Treatment in Adults with Schizophrenia |
| Q21260310 | A long-term, phase 2, multicenter, randomized, open-label, comparative safety study of pomaglumetad methionil (LY2140023 monohydrate) versus atypical antipsychotic standard of care in patients with schizophrenia |
| Q37343588 | A naturalistic comparison of the efficacy and safety of intramuscular olanzapine and intramuscular haloperidol in agitated elderly patients with schizophrenia |
| Q37164506 | A naturalistic comparison of the efficacy and safety of intramuscular olanzapine and intramuscular levomepromazine in agitated elderly patients with schizophrenia |
| Q87098215 | A naturalistic comparison study of the efficacy and safety of intramuscular olanzapine, intramuscular haloperidol, and intramuscular levomepromazine in acute agitated patients with schizophrenia |
| Q37511036 | A network-based system to improve care for schizophrenia: the Medical Informatics Network Tool (MINT). |
| Q42626478 | A neuroanatomical basis for the frequency of discrete spontaneous activities in schizophrenia |
| Q37187088 | A new self-rating scale for detecting atypical or second-generation antipsychotic side effects |
| Q34210712 | A one-year prospective study of the safety, tolerability and pharmacokinetics of the highest available dose of paliperidone palmitate in patients with schizophrenia |
| Q44448282 | A pilot trial of olanzapine for the treatment of cocaine dependence |
| Q34579324 | A placebo-controlled add-on trial of the Ampakine, CX516, for cognitive deficits in schizophrenia |
| Q48247071 | A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole for the treatment of acute manic or mixed episodes in Asian patients with bipolar I disorder (the AMAZE study). |
| Q46538440 | A positron emission tomography (PET) study of cerebral dopamine D2 and serotonine 5-HT2A receptor occupancy in patients treated with cyamemazine (Tercian). |
| Q91637095 | A potential role for adjunctive omega-3 polyunsaturated fatty acids for depression and anxiety symptoms in recent onset psychosis: Results from a 16 week randomized placebo-controlled trial for participants concurrently treated with risperidone |
| Q55342505 | A preliminary study of association of genetic variants with early response to olanzapine in schizophrenia. |
| Q90953299 | A protocol in action: Recovery approach for patients within high secure care: A 20+ year follow-up |
| Q35130672 | A quantitative measure of handwriting dysfluency for assessing tardive dyskinesia |
| Q44427894 | A random-assignment, double-blind, clinical trial of once- vs twice-daily administration of quetiapine fumarate in patients with schizophrenia or schizoaffective disorder: a pilot study |
| Q91490286 | A randomised, placebo-controlled 24-week study evaluating adjunctive brexpiprazole in patients with major depressive disorder |
| Q34260074 | A randomised, placebo-controlled 52-week trial of continued quetiapine treatment in recently depressed patients with bipolar I and bipolar II disorder |
| Q37632466 | A randomized open comparison of long-acting injectable risperidone and treatment as usual for prevention of relapse, rehospitalization, and urgent care referral in community-treated patients with rapid cycling bipolar disorder |
| Q37172973 | A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP) |
| Q35529636 | A randomized trial of clozapine vs. other antipsychotics for cannabis use disorder in patients with schizophrenia |
| Q48292095 | A randomized trial of paliperidone palmitate and risperidone long-acting injectable in schizophrenia |
| Q34322964 | A randomized trial of the efficacy and safety of the H3 antagonist ABT-288 in cognitive impairment associated with schizophrenia. |
| Q73941969 | A randomized, controlled trial of a brief interventional package for schizophrenic out-patients |
| Q42686183 | A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, fluoxetine, and venlafaxine in treatment-resistant depression |
| Q37562207 | A randomized, double-blind study of the efficacy and tolerability of extended-release quetiapine fumarate (quetiapine XR) monotherapy in patients with major depressive disorder |
| Q28263502 | A randomized, double-blind, placebo-controlled comparison study of sarcosine (N-methylglycine) and D-serine add-on treatment for schizophrenia |
| Q33934688 | A randomized, double-blind, placebo-controlled trial of quetiapine in patients with bipolar disorder, mixed or depressed phase, and alcohol dependence |
| Q51385294 | A randomized, placebo-controlled trial of aripiprazole for the treatment of methamphetamine dependence and associated psychosis. |
| Q56790740 | A single-dose, randomized, double-blind, placebo-controlled trial of sublingual asenapine for acute agitation |
| Q92275785 | A study of physical anhedonia as a trait marker in schizophrenia |
| Q36092493 | A survey of the tardive dyskinesia induced by antipsychotic drugs in patients with schizophrenia |
| Q60620427 | Abnormalities in Myelination of the Superior Cerebellar Peduncle in Patients with Schizophrenia and Deficits in Movement Sequencing |
| Q24203876 | Acetylcholinesterase inhibitors for schizophrenia |
| Q35162561 | Actigraphic measurement of the effects of single-dose haloperidol and olanzapine on spontaneous motor activity in normal subjects. |
| Q48722794 | Actigraphic monitoring (actigraphy) of circadian locomotor activity in schizophrenic patients with acute neuroleptic-induced akathisia |
| Q53232477 | Active cyamemazine metabolites in patients treated with cyamemazine (Tercian®): influence on cerebral dopamine D2 and serotonin 5-HT (2A) receptor occupancy as measured by positron emission tomography (PET). |
| Q57725477 | Acute drug-induced akathisia is not associated with low serum iron status |
| Q46599084 | Acute effects of single-dose aripiprazole and haloperidol on resting cerebral blood flow (rCBF) in the human brain |
| Q46391646 | Added donepezil for stable schizophrenia: a double-blind, placebo-controlled trial |
| Q54255083 | Addition of lithium to haloperidol in non-affective, antipsychotic non-responsive schizophrenia: a double blind, placebo controlled, parallel design clinical trial. |
| Q38348025 | Adherence and Continuation of Treatment with First- and Second-generation Antipsychotics in Schizophrenia |
| Q89136911 | Adjunct Aripiprazole Reduces Prolactin and Prolactin-Related Adverse Effects in Premenopausal Women With Psychosis: Results From the DAAMSEL Clinical Trial |
| Q42624190 | Adjunct extended-release valproate semisodium in late life schizophrenia |
| Q30490025 | Adjunctive aripiprazole in risperidone-induced hyperprolactinaemia: double-blind, randomised, placebo-controlled trial. |
| Q90436208 | Adjunctive brexpiprazole for elderly patients with major depressive disorder: An open-label, long-term safety and tolerability study |
| Q37339751 | Adjunctive brexpiprazole in patients with major depressive disorder and anxiety symptoms: an exploratory study |
| Q34350145 | Adjunctive lisdexamfetamine dimesylate therapy in adult outpatients with predominant negative symptoms of schizophrenia: open-label and randomized-withdrawal phases |
| Q34129991 | Adjunctive risperidone for partially responsive people with schizophrenia treated with clozapine |
| Q50750840 | Adjunctive sarcosine plus benzoate improved cognitive function in chronic schizophrenia patients with constant clinical symptoms: A randomised, double-blind, placebo-controlled trial. |
| Q43550823 | Aggressive and violent behavior in a population of psychiatric inpatients |
| Q73841350 | Aggressive behaviour in schizophrenia: role of state versus trait factors |
| Q41902942 | Agomelatine-induced akathisia in a 38-year-old woman with depression. |
| Q92284866 | Akathisia Induced by Abrupt Withdrawal of Risperidone: A Case Report |
| Q51944435 | Akathisia treated with olanzapine: Three case reports. |
| Q34480962 | Akathisia--a brief review |
| Q41376915 | Akathisia: a life-threatening side effect of a common medication |
| Q34062710 | Akathisia: a review and case report following paroxetine treatment |
| Q34582587 | Akathisia: problem of history or concern of today |
| Q37122386 | Altered heart rate dynamics associated with antipsychotic-induced subjective restlessness in patients with schizophrenia |
| Q37538951 | Amisulpride - dose, plasma concentration, occupancy and response: implications for therapeutic drug monitoring |
| Q55423236 | Amisulpride augmentation of clozapine for treatment-refractory schizophrenia: a double-blind, placebo-controlled trial. |
| Q31083696 | Amisulpride for schizophrenia |
| Q46203569 | Amisulpride for the treatment of very-late-onset schizophrenia-like psychosis |
| Q24656287 | Amisulpride plus valproate vs haloperidol plus valproate in the treatment of acute mania of bipolar I patients: a multicenter, open-label, randomized, comparative trial |
| Q60445497 | Amisulpride vs. risperidone in the treatment of acute exacerbations of schizophrenia |
| Q34426638 | Amoxapine as an atypical antipsychotic: a comparative study vs risperidone |
| Q34157447 | Amoxapine shows atypical antipsychotic effects in patients with schizophrenia: results from a prospective open-label study |
| Q37299870 | An Open Label Pilot Study of Adjunctive Asenapine for the Treatment of Posttraumatic Stress Disorder |
| Q64254066 | An exploratory study from eastern India on neurological soft signs and spontaneous movement disorders in schizophrenia spectrum disorders |
| Q37423561 | An open pilot study of the combination of escitalopram and bupropion-SR for outpatients with major depressive disorder |
| Q54056096 | An open study of the pharmacokinetics and the tolerability of raclopride extended release capsules in psychiatric patients. |
| Q33921598 | An open study of tolerability and pharmacokinetics of raclopride extended release capsules in psychiatric patients: a Canadian study |
| Q37409074 | An open-label extension study of the safety and efficacy of risperidone in children and adolescents with autistic disorder |
| Q35330010 | An open-label study of aripiprazole in children with a bipolar disorder |
| Q36373454 | An open-label, multicenter evaluation of the long-term safety and efficacy of risperidone in adolescents with schizophrenia |
| Q40898013 | Antagonist and partial agonist at the dopamine D2 receptors in drug-naïve and non-drug-naïve schizophrenia: a randomized, controlled trial |
| Q37696215 | Antidepressant response to aripiprazole augmentation associated with enhanced FDOPA utilization in striatum: a preliminary PET study |
| Q24186594 | Antiglucocorticoid and related treatments for psychosis |
| Q40474904 | Antipsychotic Adherence Intervention for Veterans over 40 with Schizophrenia: Results of a Pilot Study. |
| Q38704394 | Antipsychotic combinations for schizophrenia. |
| Q30475844 | Antipsychotic dose and diminished neural modulation: a multi-site fMRI study |
| Q37953186 | Antipsychotic drugs and extrapyramidal side effects in first episode psychosis: a systematic review of head-head comparisons |
| Q53916277 | Antipsychotic effects and tolerability of the sigma ligand EMD 57445 (panamesine) and its metabolites in acute schizophrenia: an open clinical trial. |
| Q24244883 | Antipsychotic medication for elderly people with schizophrenia |
| Q38611031 | Antipsychotic medication side effect assessment tools: A systematic review. |
| Q50159735 | Antipsychotic reduction and/or cessation and antipsychotics as specific treatments for tardive dyskinesia |
| Q34418584 | Antipsychotic-induced movement disorders: evaluation and treatment. |
| Q30501284 | Antipsychotic-induced vacuous chewing movements and extrapyramidal side effects are highly heritable in mice. |
| Q24245145 | Antipsychotics for delirium |
| Q38611406 | Anxiety in Patients with Schizophrenia: Epidemiology and Management |
| Q33976751 | Are cannabis use disorders associated with an earlier age at onset of psychosis? A study in first episode schizophrenia |
| Q36784527 | Are second generation antipsychotics a distinct class? |
| Q33614458 | Aripiprazole Once-Monthly 400 mg: Comparison of Pharmacokinetics, Tolerability, and Safety of Deltoid Versus Gluteal Administration |
| Q28073540 | Aripiprazole and Acute Extrapyramidal Symptoms in Children and Adolescents: A Meta-Analysis |
| Q36494728 | Aripiprazole and Risperidone for Treatment of Methamphetamine-Associated Psychosis in Chinese Patients |
| Q43145175 | Aripiprazole as adjunct to a mood stabilizer and citalopram in bipolar depression: a randomized placebo-controlled pilot study |
| Q79366637 | Aripiprazole augmentation for treatment of patients with inadequate antidepressants response |
| Q39304379 | Aripiprazole augmentation in major depressive disorder: a double-blind, placebo-controlled study in patients with inadequate response to antidepressants |
| Q33841432 | Aripiprazole effects on self-administration and pharmacodynamics of intravenous cocaine and cigarette smoking in humans |
| Q26471439 | Aripiprazole for autism spectrum disorders (ASD) |
| Q47392599 | Aripiprazole for cocaine abstinence: a randomized-controlled trial with ecological momentary assessment |
| Q46111844 | Aripiprazole for patients with schizophrenia and schizoaffective disorder: an open-label, randomized, study versus haloperidol |
| Q48258866 | Aripiprazole in combination with lamotrigine for the long-term treatment of patients with bipolar I disorder (manic or mixed): a randomized, multicenter, double-blind study (CN138-392). |
| Q38076765 | Aripiprazole in the treatment of Alzheimer's disease |
| Q46886132 | Aripiprazole in the treatment of acute manic or mixed episodes in patients with bipolar I disorder: a 3-week placebo-controlled study |
| Q34734254 | Aripiprazole is associated with early onset of Tardive Dyskinesia like presentation in a patient with ABI and psychosis |
| Q40765718 | Aripiprazole once-monthly 400 mg for long-term maintenance treatment of schizophrenia: a 52-week open-label study |
| Q89052840 | Aripiprazole once-monthly as maintenance treatment for bipolar I disorder: a 52-week, multicenter, open-label study |
| Q48793990 | Aripiprazole plus divalproex for recently manic or mixed patients with bipolar I disorder: a 6-month, randomized, placebo-controlled, double-blind maintenance trial |
| Q35684487 | Aripiprazole versus haloperidol treatment in early-stage schizophrenia |
| Q24200904 | Aripiprazole versus other atypical antipsychotics for schizophrenia |
| Q24201232 | Aripiprazole versus other atypical antipsychotics for schizophrenia |
| Q24240020 | Aripiprazole versus other atypical antipsychotics for schizophrenia |
| Q38122151 | Aripiprazole: a review of its use in the treatment of irritability associated with autistic disorder patients aged 6-17. |
| Q37866291 | Aripiprazole: in the treatment of irritability associated with autistic disorder in pediatric patients |
| Q47796261 | Asenapine for the treatment of adults with an acute exacerbation of schizophrenia: results from a randomized, double-blind, fixed-dose, placebo-controlled trial with olanzapine as an active control |
| Q36794665 | Asenapine in the treatment of older adults with bipolar disorder |
| Q24187667 | Asenapine versus placebo for schizophrenia |
| Q38070179 | Asenapine, iloperidone and lurasidone: critical appraisal of the most recently approved pharmacotherapies for schizophrenia in adults |
| Q52128586 | Asperger's disorder in the emergency psychiatric setting. |
| Q38438276 | Association between restless legs syndrome and CLOCK and NPAS2 gene polymorphisms in schizophrenia. |
| Q33244596 | Association between two distinct executive tasks in schizophrenia: a functional transcranial Doppler sonography study |
| Q36148530 | Association of a Schizophrenia Risk Variant at the DRD2 Locus With Antipsychotic Treatment Response in First-Episode Psychosis |
| Q50794479 | Association of two DRD2 gene polymorphisms with acute and tardive antipsychotic-induced movement disorders in young Caucasian patients. |
| Q45167369 | Association study between antipsychotic-induced restless legs syndrome and polymorphisms of monoamine oxidase genes in schizophrenia |
| Q47300367 | Attenuating effect of reboxetine on appetite and weight gain in olanzapine-treated schizophrenia patients: a double-blind placebo-controlled study |
| Q86978635 | Attitude towards second-generation antipsychotics among patients with schizophrenia and their relatives |
| Q33908823 | Attitudes towards antipsychotics among patients with schizophrenia on first- or second-generation medications |
| Q44858913 | Atypical antipsychotic drugs and tardive dyskinesia: relevance of D2 receptor affinity |
| Q24197475 | Atypical antipsychotics for psychosis in adolescents |
| Q40824970 | Atypical antipsychotics. Part I: Pharmacology, pharmacokinetics, and efficacy |
| Q33539480 | Behavioural problems associated with dementia: the role of newer antipsychotics |
| Q41891428 | Benefical effects of sigma-1 agonist fluvoxamine for tardive dyskinesia and tardive akathisia in patients with schizophrenia: report of three cases |
| Q30820759 | Benzodiazepines for neuroleptic-induced acute akathisia. |
| Q45998558 | Biological perspectives: akathisia: ants in your pants. |
| Q36443793 | Brain structure and function correlates of cognitive subtypes in schizophrenia |
| Q37100358 | Brain-performance correlates of working memory retrieval in schizophrenia: a cognitive modeling approach |
| Q48169685 | Brainstem reflexes are hyperactive in patients with drug-induced akathisia |
| Q39009497 | Brexpiprazole in patients with schizophrenia: overview of short- and long-term phase 3 controlled studies |
| Q26766401 | Brexpiprazole: so far so good |
| Q46886103 | Cannabidiol monotherapy for treatment-resistant schizophrenia |
| Q64954388 | Cariprazine Augmentation to Antidepressant Therapy in Major Depressive Disorder: Results of a Randomized, Double-Blind, Placebo-Controlled Trial. |
| Q36530048 | Cariprazine in the treatment of schizophrenia: a proof-of-concept trial |
| Q46258857 | Cataractogenic potential of quetiapine versus risperidone in the long-term treatment of patients with schizophrenia or schizoaffective disorder: a randomized, open-label, ophthalmologist-masked, flexible-dose, non-inferiority trial |
| Q44936215 | Changes in plasma concentrations of risperidone and 9-hydroxyrisperidone and the associated clinical effects during the switch from oral risperidone to extended-release paliperidone tablets in patients with schizophrenia |
| Q50264113 | Characterization of spontaneous Parkinsonism in drug-naive patients with nonaffective psychotic disorders |
| Q37451422 | Characterization of the deficit syndrome in drug-naive schizophrenia patients: the role of spontaneous movement disorders and neurological soft signs. |
| Q37212118 | Choice of randomization to clozapine versus other second generation antipsychotics in the CATIE schizophrenia trial |
| Q89166417 | Clinical Predictors of Extrapyramidal Symptoms Associated With Aripiprazole Augmentation for the Treatment of Late-Life Depression in a Randomized Controlled Trial |
| Q43861966 | Clinical advantages of amisulpride in the treatment of acute schizophrenia |
| Q51952437 | Clinical characteristics and associated factors in antipsychotic-induced akathisia of Asian patients with schizophrenia. |
| Q47822171 | Clinical correlates of clozapine prescription for schizophrenia in China. |
| Q40549838 | Clinical correlates of early medication adherence: West London first episode schizophrenia study |
| Q24240093 | Clozapine combined with different antipsychotic drugs for treatment resistant schizophrenia |
| Q57014103 | Clozapine effectiveness in a psychiatric service in Italy |
| Q24187048 | Clozapine for psychotic disorders in adults with intellectual disabilities |
| Q61795776 | Clozapine in the Treatment of Aggression in Conduct Disorder in Children and Adolescents: A Randomized, Double-blind, Controlled Trial |
| Q24236422 | Clozapine versus other atypical antipsychotics for schizophrenia |
| Q60047653 | Cognitive and Functional Assessment of Psychosis Stratification Study (CoFAPSS): Rationale, Design, and Characteristics |
| Q34603527 | Cognitive effects of antipsychotic dosage and polypharmacy: a study with the BACS in patients with schizophrenia and schizoaffective disorder |
| Q41454443 | Comments on Lucire and Crotty, 2011. |
| Q34496764 | Community adherence to schizophrenia treatment and safety monitoring guidelines |
| Q74594331 | Comparative efficacy of olanzapine and haloperidol for patients with treatment-resistant schizophrenia |
| Q53519349 | Comparative evaluation of conventional and novel antipsychotic drugs with reference to their subjective tolerability, side-effect profile and impact on quality of life. |
| Q48063467 | Comparing antipsychotic treatments for schizophrenia: a health state approach |
| Q51915861 | Comparison between risperidone, olanzapine, and clozapine in the management of chronic schizophrenia: a naturalistic prospective 12-week observational study. |
| Q27320151 | Comparison of SGA oral medications and a long-acting injectable SGA: the PROACTIVE study |
| Q43856623 | Comparison of risperidone with olanzapine in elderly patients with dementia and psychosis |
| Q41686490 | Comparison of the effect of lithium plus quetiapine with lithium plus risperidone in children and adolescents with bipolar I disorder: a randomized clinical trial |
| Q36597242 | Compliance therapy in psychotic patients: randomised controlled trial |
| Q52135570 | Conditioned blocking and schizophrenia: a replication and study of the role of symptoms, age, onset-age of psychosis and illness-duration. |
| Q38006526 | Conformance to evidence-based treatment recommendations in schizophrenia treatment services |
| Q102328391 | Continuation phase treatment outcomes for switching, combining, or augmenting strategies for treatment-resistant major depressive disorder: A VAST-D report |
| Q38364288 | Cost-effectiveness of early responders versus early nonresponders to atypical antipsychotic therapy |
| Q38497334 | Cost-effectiveness of olanzapine vs. aripiprazole in the treatment of schizophrenia |
| Q35693485 | Course of neurological soft signs in first-episode schizophrenia: Relationship with negative symptoms and cognitive performances |
| Q37137005 | Cross-sectional and longitudinal relationships between insight and attitudes toward medication and clinical outcomes in chronic schizophrenia |
| Q34068005 | D-serine added to antipsychotics for the treatment of schizophrenia |
| Q44203842 | DRD2/ANKK1 Taq1A (rs 1800497 C>T) genotypes are associated with susceptibility to second generation antipsychotic-induced akathisia. |
| Q34028165 | Delayed-onset akathisia due to amisulpride |
| Q74363092 | Depression measures and motor side-effects in patients with acute schizophrenia |
| Q43772144 | Depressive symptoms in stable chronic schizophrenia: prevalence and relationship to psychopathology and treatment |
| Q24623483 | Development and Psychometric Evaluation of the Treatment-Emergent Activation and Suicidality Assessment Profile |
| Q57191056 | Development and clinimetric assessment of a nurse-administered screening tool for movement disorders in psychosis |
| Q51952558 | Diabetes is not a risk factor for tardive dyskinesia: a retrospective observational study. |
| Q37062577 | Direct and indirect effects of paliperidone extended-release tablets on negative symptoms of schizophrenia. |
| Q92132960 | Discerning undifferentiated anxiety from syndromal anxiety in acute-phase schizophrenia |
| Q36857163 | Disrupted central inhibition after transcranial magnetic stimulation of motor cortex in schizophrenia with long-term antipsychotic treatment |
| Q77813843 | Does akathisia influence psychopathology in psychotic patients treated with clozapine? |
| Q60440906 | Dopamine D2 receptor blockade in vivo with the novel antipsychotics risperidone and remoxipride — an123I-IBZM single photon emission tomography (SPET) study |
| Q73477695 | Dopamine D2 receptor occupancy by olanzapine or risperidone in young patients with schizophrenia |
| Q49068807 | Dopamine D2 receptor occupancy in vivo by the novel atypical antipsychotic olanzapine--a 123I IBZM single photon emission tomography (SPET) study |
| Q93200965 | Dopamine D2 receptor occupancy of lumateperone (ITI-007): a Positron Emission Tomography Study in patients with schizophrenia |
| Q35537262 | Dopamine D₂/₃ receptor availability in the striatum of antipsychotic-free older patients with schizophrenia-A [¹¹C]-raclopride PET study |
| Q31861860 | Dopamine transporter density in young patients with schizophrenia assessed with [123]FP-CIT SPECT. |
| Q31864356 | Double-blind comparison of olanzapine versus clozapine in schizophrenic patients clinically eligible for treatment with clozapine |
| Q33902228 | Double-blind maintenance safety and effectiveness findings from the Treatment of Early-Onset Schizophrenia Spectrum (TEOSS) study |
| Q43724641 | Double-blind olanzapine vs. haloperidol D2 dopamine receptor blockade in schizophrenic patients: a baseline-endpoint. |
| Q34455825 | Double‐blind randomized trial of risperidone versus divalproex in pediatric bipolar disorder |
| Q94563262 | Drug-Drug-Induced Akathisia: Two Case Reports |
| Q41387751 | Drug-induced Extrapyramidal Symptoms Scale (DIEPSS) Serbian Language version: Inter-rater and Test-retest Reliability. |
| Q34308560 | Drug-induced akathisia - a preliminary report |
| Q84543334 | D₂-receptor occupancy measurement of JNJ-37822681, a novel fast off-rate D₂-receptor antagonist, in healthy subjects using positron emission tomography: single dose versus steady state and dose selection |
| Q24243986 | Early Intervention for psychosis |
| Q39460348 | Early intervention and evaluation for adult-onset psychosis: the JCEP study rationale and design. |
| Q24236296 | Early intervention for psychosis |
| Q37409087 | Early nonresponse determined by the clinical global impressions scale predicts poorer outcomes in youth with schizophrenia spectrum disorders naturalistically treated with second-generation antipsychotics |
| Q46732380 | Early predictors of nonadherence to antipsychotic therapy in first-episode psychosis |
| Q40881518 | Early response or nonresponse at week 2 and week 3 predict ultimate response or nonresponse in adolescents with schizophrenia treated with olanzapine: results from a 6-week randomized, placebo-controlled trial. |
| Q34660736 | Early response to antipsychotic drug therapy as a clinical marker of subsequent response in the treatment of schizophrenia |
| Q57602644 | Effect of CYP2D6 on risperidone pharmacokinetics and extrapyramidal symptoms in healthy volunteers: results from a pharmacogenetic clinical trial |
| Q92724199 | Effect of Continuing Olanzapine vs Placebo on Relapse Among Patients With Psychotic Depression in Remission: The STOP-PD II Randomized Clinical Trial |
| Q55255712 | Effect of Vitamin B6 Versus Propranolol on Antipsychotic-Induced Akathisia: A pilot Comparative Double-blind Study. |
| Q33185518 | Effect of divalproex combined with olanzapine or risperidone in patients with an acute exacerbation of schizophrenia |
| Q57526943 | Effectiveness Study of Venlafaxine-XR Combined with Aripiprazole for Chronic or Recurrent Major Depressive Disorder |
| Q42688877 | Effectiveness of haloperidol, risperidone and olanzapine in the treatment of first-episode non-affective psychosis: results of a randomized, flexible-dose, open-label 1-year follow-up comparison |
| Q34073723 | Effectiveness of lurasidone in schizophrenia or schizoaffective patients switched from other antipsychotics: a 6-month, open-label, extension study |
| Q92194108 | Effects of 6-Week Use of Very Low Nicotine Content Cigarettes in Smokers With Serious Mental Illness |
| Q47739996 | Effects of Extended Cannabis Abstinence on Cognitive Outcomes in Cannabis Dependent Patients with Schizophrenia vs Non-Psychiatric Controls |
| Q51968316 | Effects of amisulpride on the cognitive function of patients with schizophrenia who switched from risperidone. |
| Q45743617 | Effects of antipsychotic treatment on cognition in healthy subjects |
| Q84280631 | Effects of antipsychotic treatment on psychopathology and motor symptoms. A placebo-controlled study in healthy volunteers |
| Q47845091 | Effects of aripiprazole and haloperidol on neural activation during a simple motor task in healthy individuals: A functional MRI study |
| Q43744300 | Effects of chronic haloperidol and clozapine treatments on frontal and caudate neurochemistry in schizophrenia. |
| Q36936916 | Effects of contingency management and bupropion on cigarette smoking in smokers with schizophrenia |
| Q47621751 | Effects of d-amphetamine and haloperidol on latent inhibition in healthy male volunteers |
| Q33886277 | Effects of haloperidol on the behavioral, subjective, cognitive, motor, and neuroendocrine effects of Delta-9-tetrahydrocannabinol in humans |
| Q71681126 | Effects of raclopride treatment on plasma and CSF HVA: relationships with clinical improvement in male schizophrenics |
| Q34568196 | Effects of risperidone augmentation in patients with treatment-resistant depression: Results of open-label treatment followed by double-blind continuation |
| Q43269341 | Effects of switching to long-acting injectable risperidone from oral atypical antipsychotics on cognitive function in patients with schizophrenia |
| Q37029513 | Effects of the cannabinoid-1 receptor antagonist rimonabant on psychiatric symptoms in overweight people with schizophrenia: a randomized, double-blind, pilot study |
| Q33625354 | Efficacy and Safety of Brexpiprazole (OPC-34712) as Maintenance Treatment in Adults with Schizophrenia: a Randomized, Double-Blind, Placebo-Controlled Study |
| Q92492120 | Efficacy and Safety of Lumateperone for Treatment of Schizophrenia: A Randomized Clinical Trial |
| Q41495591 | Efficacy and Safety of Lurasidone in Adolescents with Schizophrenia: A 6-Week, Randomized Placebo-Controlled Study |
| Q37299902 | Efficacy and Safety of Paliperidone Extended Release 1.5 mg/day-A Double-blind, Placebo- and Active-Controlled, Study in the Treatment of Patients with Schizophrenia |
| Q37160642 | Efficacy and Tolerability of Paliperidone Extended-release in the Treatment of First-episode Psychosis: An Eight-week, Open-label, Multicenter Trial |
| Q35683821 | Efficacy and safety of aripiprazole once-monthly in obese and nonobese patients with schizophrenia: a post hoc analysis |
| Q40195274 | Efficacy and safety of donepezil in patients with schizophrenia or schizoaffective disorder: significant placebo/practice effects in a 12-week, randomized, double-blind, placebo-controlled trial |
| Q34393030 | Efficacy and safety of olanzapine/fluoxetine combination vs fluoxetine monotherapy following successful combination therapy of treatment-resistant major depressive disorder |
| Q102388982 | Efficacy and safety of once-monthly Risperidone ISM® in schizophrenic patients with an acute exacerbation |
| Q45928081 | Efficacy and safety of quetiapine for depressive symptoms in patients with schizophrenia. |
| Q26781173 | Efficacy and tolerability of aripiprazole once monthly for schizophrenia: a systematic review and meta-analysis of randomized controlled trials |
| Q42928152 | Efficacy and tolerability of extended release quetiapine fumarate monotherapy as maintenance treatment of major depressive disorder: a randomized, placebo-controlled trial |
| Q59128324 | Efficacy of adjunctive low-dose cariprazine in major depressive disorder: a randomized, double-blind, placebo-controlled trial |
| Q34665354 | Efficacy of amisulpride and olanzapine for negative symptoms and cognitive impairments: An open-label clinical study |
| Q48310435 | Efficacy of aripiprazole adjunctive to lithium or valproate in the long-term treatment of patients with bipolar I disorder with an inadequate response to lithium or valproate monotherapy: a multicenter, double-blind, randomized study |
| Q93184949 | Efficacy of low-dose D2/D3 partial agonist pramipexole on neuroleptic-induced extrapyramidal symptoms and symptoms of schizophrenia: a stage-1 open-label pilot study |
| Q44263553 | Efficacy of olanzapine in social anxiety disorder: a pilot study |
| Q34286350 | Efficacy of olanzapine long-acting injection in patients with acutely exacerbated schizophrenia: an insight from effect size comparison with historical oral data |
| Q41592066 | Efficacy of second-generation antipsychotics in patients at ultra-high risk and those with first-episode or multi-episode schizophrenia |
| Q37244172 | Efficacy, long-term safety, and tolerability of ziprasidone in children and adolescents with bipolar disorder |
| Q37737291 | Efficacy, safety and tolerability of Symbyax for acute-phase management of treatment-resistant depression |
| Q42707279 | Escitalopram-induced severe akathisia: a case report. |
| Q33518314 | Evaluation of akathisia in patients with schizophrenia, schizoaffective disorder, or bipolar I disorder: a post hoc analysis of pooled data from short- and long-term aripiprazole trials |
| Q89714970 | Evaluation of cariprazine in the treatment of bipolar I and II depression: a randomized, double-blind, placebo-controlled, phase 2 trial |
| Q30792325 | Evaluation of different approaches for confounding in nonrandomised observational data: a case-study of antipsychotics treatment |
| Q37436084 | Evaluation of subjective effects of aripiprazole and methamphetamine in methamphetamine-dependent volunteers. |
| Q47733836 | Evaluation of the long-term safety and tolerability of cariprazine in patients with schizophrenia: results from a 1-year open-label study |
| Q30844805 | Evidence and consensus recommendations for the pharmacological management of pain in India |
| Q50892054 | Evolution and post-traumatic stress disorder. |
| Q34994773 | Evolution of Substance use, Neurological and Psychiatric Symptoms in Schizophrenia and Substance use Disorder Patients: A 12-Week, Pilot, Case-Control Trial with Quetiapine |
| Q45343746 | Examining gender difference in adult-onset psychosis in Hong Kong |
| Q46578040 | Executive function assessment of patients with schizophrenic disorder residual type in olanzapine treatment: an open study |
| Q36700337 | Expert Canadian consensus suggestions on the rational, clinical use of ziprasidone in the treatment of schizophrenia and related psychotic disorders |
| Q80068446 | Exploring the clinical and social determinants of prescribing anticholinergic medication for Chinese patients with schizophrenia |
| Q41283976 | Exploring the long-term safety of asenapine in adults with schizophrenia in a double-blind, fixed-dose, extension study |
| Q37299893 | Extended Release Quetiapine Fumarate (Quetiapine XR) as Adjunct Therapy in Patients with Generalized Anxiety Disorder and a History of Inadequate Treatment Response: A Randomized, Double-Blind Study |
| Q43153951 | Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant treatment: a multicentre, randomized, double-blind, placebo-controlled st |
| Q30492645 | Extrapyramidal side-effects of antipsychotics in a randomised trial |
| Q51952586 | Extrapyramidal symptoms and residual psychopathology with low-dose neuroleptics. |
| Q46486034 | Extrapyramidal symptoms and signs in first-episode, antipsychotic exposed and non-exposed patients with schizophrenia or related psychotic illness. |
| Q28236854 | Extrapyramidal symptoms with atypical antipsychotics : incidence, prevention and management |
| Q93144039 | Eye movements and neurocognitive function in treatment resistant schizophrenia: a pilot study |
| Q41629589 | Factors associated with self-rated sexual function in Korean patients with schizophrenia receiving risperidone monotherapy |
| Q91466571 | Factors associated with successful antipsychotic dose reduction in schizophrenia: a systematic review of prospective clinical trials and meta-analysis of randomized controlled trials |
| Q28277784 | Feasibility, safety, and efficacy of the combination of D-serine and computerized cognitive retraining in schizophrenia: an international collaborative pilot study. |
| Q33488312 | Fluoxetine and olanzapine combination therapy in treatment-resistant major depression: review of efficacy and safety data |
| Q43812583 | Fluphenazine plasma level monitoring for patients receiving fluphenazine decanoate |
| Q39852066 | Fluvoxamine for aripiprazole-associated akathisia in patients with schizophrenia: a potential role of sigma-1 receptors |
| Q40489548 | Fluvoxamine for blonanserin-associated akathisia in patients with schizophrenia: report of five cases. |
| Q46696089 | Further evidence for association of the RGS2 gene with antipsychotic-induced parkinsonism: protective role of a functional polymorphism in the 3'-untranslated region |
| Q59813199 | Gabapentin enacarbil for antipsychotic induced akathisia in schizophrenia patients: a pilot open-labeled study |
| Q48831748 | Gender differences in sociodemographic and clinical characteristic and the quality of life of Chinese schizophrenia patients. |
| Q39292622 | Genetic Risk and Outcome of Psychosis (GROUP), a multi-site longitudinal cohort study focused on gene-environment interaction: objectives, sample characteristics, recruitment and assessment methods. |
| Q35010386 | Genomewide association study of movement-related adverse antipsychotic effects |
| Q51948554 | Glasgow's community care programme: 10 year follow up of discharged patients with schizophrenia. |
| Q34424470 | Glutamate as a marker of cognitive function in schizophrenia: a proton spectroscopic imaging study at 4 Tesla. |
| Q48557473 | Glutamatergic and Neuronal Dysfunction in Gray and White Matter: A Spectroscopic Imaging Study in a Large Schizophrenia Sample |
| Q24203034 | Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) |
| Q38652475 | Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation). |
| Q24241801 | Haloperidol plus promethazine for psychosis-induced aggression |
| Q24245745 | Haloperidol plus promethazine for psychosis-induced aggression |
| Q34545855 | Haloperidol plus promethazine for psychosis-induced aggression. |
| Q24202457 | Haloperidol versus placebo for schizophrenia |
| Q33811763 | Handwriting movement kinematics for quantifying extrapyramidal side effects in patients treated with atypical antipsychotics |
| Q48501616 | Haplotype Association of the MAP2K5 Gene with Antipsychotics-Induced Symptoms of Restless Legs Syndrome among Patients with Schizophrenia |
| Q37399425 | Heavy Alcohol Drinking Associated Akathisia and Management with Quetiapine XR in Alcohol Dependent Patients |
| Q36479590 | Hemodynamic response function abnormalities in schizophrenia during a multisensory detection task |
| Q35034312 | High dose D-serine in the treatment of schizophrenia |
| Q24814459 | Hostility and violence of acute psychiatric inpatients |
| Q24289439 | Hostility in schizophrenia: An integrated analysis of the combined Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) and the European First Episode Schizophrenia Trial (EUFEST) studies |
| Q50302677 | Hyperkinesias in a prepubertal boy with autistic disorder treated with haloperidol and valproic acid. |
| Q37768462 | Iloperidone for schizophrenia |
| Q37834873 | Iloperidone: A new drug for the treatment of schizophrenia |
| Q39043789 | Immediate vs Gradual Discontinuation in Antipsychotic Switching: A Systematic Review and Meta-analysis |
| Q51894942 | Impact of the priority follow-up system on quality of life in Chinese schizophrenia patients. |
| Q47744849 | Impaired subjective well-being in schizophrenia is associated with reduced anterior cingulate activity during reward processing. |
| Q37221567 | Improvement in social and cognitive functioning associated with paliperidone extended-release treatment in patients with schizophrenia: a 24-week, single arm, open-label study |
| Q39924654 | Improvement in social competence in patients with schizophrenia: a pilot study using a performance-based measure using virtual reality |
| Q35069246 | Improving delirium care in the intensive care unit: the design of a pragmatic study |
| Q48683589 | In vivo quantification of striatal dopamine D2 receptor occupancy by JNJ-37822681 using [11C]raclopride and positron emission tomography |
| Q47707388 | Incidence and risk factors of acute akathisia in 493 individuals with first episode non-affective psychosis: a 6-week randomised study of antipsychotic treatment |
| Q41862402 | Incidence and time course of extrapyramidal symptoms with oral and long-acting injectable paliperidone: a posthoc pooled analysis of seven randomized controlled studies |
| Q36773233 | Incidence of adverse events in antipsychotic-naïve children and adolescents treated with antipsychotic drugs: a French multicentre naturalistic study protocol (ETAPE) |
| Q46079349 | Incidence of tardive dyskinesia in older adult patients treated with olanzapine or conventional antipsychotics |
| Q36142165 | Increased extrapyramidal symptoms in patients with schizophrenia and a comorbid substance use disorder |
| Q57689312 | Increasing antipsychotic dose for non response in schizophrenia |
| Q34386756 | Incremental dosage of the new antipsychotic mazapertine induces tolerance to cardiovascular and cognitive effects in healthy men. |
| Q44900131 | Influence of ANKK1 and DRD2 polymorphisms in response to haloperidol |
| Q72483607 | Influence of rate of administration of raclopride on akathisia and prolactin response |
| Q46549460 | Interrater reliability of the Antipsychotic Non-Neurological Side-Effects Rating Scale measured in patients treated with clozapine |
| Q24243093 | Interventions to reduce weight gain in schizophrenia |
| Q51912991 | Intramuscular aripiprazole for the treatment of acute agitation in patients with schizophrenia or schizoaffective disorder: a double-blind, placebo-controlled comparison with intramuscular haloperidol. |
| Q43689758 | Intramuscular olanzapine and intramuscular haloperidol in acute schizophrenia: antipsychotic efficacy and extrapyramidal safety during the first 24 hours of treatment |
| Q51973741 | Intravenous biperiden in akathisia: an open pilot study. |
| Q74148025 | Is akathisia associated with poor clinical response to antipsychotics during acute hospital treatment? |
| Q34515834 | LURASIDONE IN THE LONG-TERM TREATMENT OF PATIENTS WITH BIPOLAR DISORDER: A 24-WEEK OPEN-LABEL EXTENSION STUDY |
| Q34373482 | Lack of apparent antipsychotic effect of the D1-dopamine receptor antagonist SCH39166 in acutely ill schizophrenic patients |
| Q51828618 | Lack of association between 71 variations located in candidate genes and response to acute haloperidol treatment. |
| Q41656833 | Lack of association between dopaminergic antagonism and negative symptoms in schizophrenia: a positron emission tomography dopamine D2/3 receptor occupancy study |
| Q93564857 | Les recommandations thérapeutiques relatives aux effets secondaires extrapyramidaux associés à l’utilisation d’antipsychotiques de deuxième génération chez les enfants et les adolescents |
| Q34346051 | Liquid risperidone in the treatment of rages in psychiatrically hospitalized children with possible bipolar disorder |
| Q34474219 | Lithium as add-on to quetiapine XR in adult patients with acute mania: a 6-week, multicenter, double-blind, randomized, placebo-controlled study |
| Q24186325 | Lithium for schizophrenia |
| Q94560359 | Long-Term Safety and Durability of Effect With a Combination of Olanzapine and Samidorphan in Patients With Schizophrenia: Results From a 1-Year Open-Label Extension Study |
| Q38115487 | Long-acting injectable formulations of new-generation antipsychotics: a review from a clinical perspective |
| Q28477329 | Long-stay psychiatric patients: a prospective study revealing persistent antipsychotic-induced movement disorder |
| Q42608128 | Long-term (3-year) effectiveness of haloperidol, risperidone and olanzapine: results of a randomized, flexible-dose, open-label comparison in first-episode nonaffective psychosis |
| Q45899470 | Long-term (3-year) neurocognitive effectiveness of antipsychotic medications in first-episode non-affective psychosis: a randomized comparison of haloperidol, olanzapine, and risperidone. |
| Q37500576 | Long-term Efficacy and Tolerability of Perospirone for Young Help-seeking People at Clinical High Risk: a Preliminary Open Trial |
| Q52650011 | Long-term effects of discontinuation from antipsychotic maintenance following first-episode schizophrenia and related disorders: a 10 year follow-up of a randomised, double-blind trial. |
| Q43827160 | Long-term efficacy of olanzapine in the control of psychotic and behavioral symptoms in nursing home patients with Alzheimer's dementia |
| Q89128745 | Long-term safety and effectiveness of lurasidone in schizophrenia: a 22-month, open-label extension study |
| Q34293899 | Long-term safety and efficacy of olanzapine long-acting injection in patients with schizophrenia or schizoaffective disorder: a 6-year, multinational, single-arm, open-label study |
| Q62842047 | Long-term safety and tolerability of cariprazine as adjunctive therapy in major depressive disorder |
| Q48201230 | Long-term safety and tolerability of iloperidone: results from a 25-week, open-label extension trial |
| Q34027230 | Long-term safety and tolerability of open-label aripiprazole augmentation of antidepressant therapy in major depressive disorder |
| Q37675302 | Long-term use of lurasidone in patients with bipolar disorder: safety and effectiveness over 2 years of treatment |
| Q88913275 | Longitudinal association between motor and obsessive compulsive symptoms in patients with psychosis and their unaffected siblings |
| Q36674291 | Lurasidone for the Treatment of Irritability Associated with Autistic Disorder |
| Q38689883 | Lurasidone for the treatment of irritability and anger in autism spectrum disorders |
| Q36537114 | Lurasidone in the treatment of schizophrenia: a 6-week, placebo-controlled study |
| Q24197902 | Maintenance treatment with antipsychotic drugs for schizophrenia |
| Q34075734 | Maintenance treatment with quetiapine versus discontinuation after one year of treatment in patients with remitted first episode psychosis: randomised controlled trial. |
| Q42603284 | Maintenance treatment with quetiapine when combined with either lithium or divalproex in bipolar I disorder: analysis of two large randomized, placebo-controlled trials |
| Q24197558 | Management of sexual dysfunction due to antipsychotic drug therapy |
| Q51956708 | Managing adverse drug reactions: an orphan task. |
| Q53905132 | Measurement of quality of life in schizophrenia: a comparison of two scales. |
| Q40645304 | Measuring costs of guideline-driven mental health care: the Texas Medication Algorithm Project |
| Q73262312 | Measuring neuroleptic-induced akathisia by three-channel actometry |
| Q44133367 | Medication adherence of individuals with a first episode of psychosis |
| Q43453594 | Medication attitudes and beliefs in patients with psychotic and affective disorders on maintenance treatment. |
| Q42701502 | Medication nonadherence among South American patients with schizophrenia. |
| Q43664089 | Meta-analysis comparing newer antipsychotic drugs for the treatment of schizophrenia: evaluating the indirect approach |
| Q34792708 | Meta-analysis of noradrenergic and specific serotonergic antidepressant use in schizophrenia |
| Q34691850 | Metabolic Abnormality and Sleep Disturbance are Associated with Clinical Severity of Patients with Schizophrenia |
| Q89091008 | Metabolic Effects of Antipsychotics on Adiposity and Insulin Sensitivity in Youths: A Randomized Clinical Trial |
| Q36225626 | Metabolic syndrome and adverse clinical outcomes in patients with bipolar disorder |
| Q92549114 | Metformin add-on vs. antipsychotic switch vs. continued antipsychotic treatment plus healthy lifestyle education in overweight or obese youth with severe mental illness: results from the IMPACT trial |
| Q57689228 | Mirtazapine adjunct for people with schizophrenia |
| Q92168500 | Monthly Extended-Release Risperidone (RBP-7000) in the Treatment of Schizophrenia: Results From the Phase 3 Program |
| Q47767785 | Motivational and neurocognitive deficits are central to the prediction of longitudinal functional outcome in schizophrenia |
| Q34369065 | Motor deficits in schizophrenia quantified by nonlinear analysis of postural sway |
| Q42167074 | Movement disorder profile and treatment outcomes in a one-year study of patients with schizophrenia |
| Q83680710 | Movement disorders are associated with schizotypy in unaffected siblings of patients with non-affective psychosis |
| Q43614716 | Movement disorders in patients with schizophrenia and a history of substance abuse |
| Q34480263 | Movement disorders induced by antipsychotic drugs: implications of the CATIE schizophrenia trial |
| Q38642322 | Movement side effects of antipsychotic drugs in adults with and without intellectual disability: UK population-based cohort study. |
| Q38622665 | Multimodal Neuroimaging in Schizophrenia: Description and Dissemination. |
| Q36723359 | Multisite, open-label, prospective trial of lamotrigine for geriatric bipolar depression: a preliminary report. |
| Q34492934 | NBI-98854, a selective monoamine transport inhibitor for the treatment of tardive dyskinesia: A randomized, double-blind, placebo-controlled study |
| Q48325930 | Neural correlates of tactile prepulse inhibition: a functional MRI study in normal and schizophrenic subjects |
| Q46808074 | Neurochemical effects of olanzapine in first-hospitalization manic adolescents: a proton magnetic resonance spectroscopy study |
| Q74074287 | Neuroleptic-induced akathisia and early onset tardive dyskinesia in affective disorder due to Cushing's syndrome |
| Q49158341 | Neurological soft signs and brain morphology in first-episode schizophrenia. |
| Q37334740 | Neurological soft signs and cognitive functions: Amongst euthymic bipolar I disorder cases, non-affected first degree relatives and healthy controls |
| Q44714810 | Neurological soft signs and neuropsychological performance in patients with first episode schizophrenia |
| Q77312681 | Neuropsychological impairment in patients treated with depot neuroleptics: a longitudinal study |
| Q37106966 | New developments in the management of major depressive disorder and generalized anxiety disorder: role of quetiapine |
| Q24247720 | New generation antipsychotics for first episode schizophrenia |
| Q42028611 | Nivolumab-Induced Severe Akathisia in an Advanced Lung Cancer Patient |
| Q58797266 | No Effect of Dose Adjustment to the Genotype in Patients With Severe Mental Illness |
| Q30424511 | No association of a set of candidate genes on haloperidol side effects |
| Q43247461 | No influence of FAT polymorphisms in response to aripiprazole |
| Q55051443 | Non-motor cognitive-perceptual dysfunction associated with drug-induced parkinsonism. |
| Q46565096 | Obsessive-compulsive disorder in UK clozapine-treated schizophrenia and schizoaffective disorder: a cause for clinical concern |
| Q73917799 | Obsessive-compulsive disorder in hospitalized patients with chronic schizophrenia |
| Q60460746 | Obstetric complications and neurological abnormalities in neuroleptic-naive psychotic patients |
| Q24244015 | Olanzapine IM or velotab for acutely disturbed/agitated people with suspected serious mental illnesses |
| Q37252495 | Olanzapine and fluoxetine combination therapy for treatment-resistant depression: review of efficacy, safety, and study design issues |
| Q38514917 | Olanzapine and risperidone plasma concentration therapeutic drug monitoring: A feasibility study. |
| Q46775465 | Olanzapine does not enhance cognition in non-agitated and non-psychotic patients with mild to moderate Alzheimer's dementia |
| Q24244031 | Olanzapine for schizophrenia |
| Q30868034 | Olanzapine for schizophrenia. |
| Q44229658 | Olanzapine for the treatment of chronic refractory schizophrenia: a 12-month follow-up naturalistic study |
| Q37400562 | Olanzapine has better efficacy compared to risperidone for treatment of negative symptoms in schizophrenia |
| Q44247108 | Olanzapine in diverse syndromal and subsyndromal exacerbations of bipolar disorders |
| Q44266760 | Olanzapine in the acute treatment of bipolar I disorder with a history of rapid cycling |
| Q44124857 | Olanzapine in the treatment of anorexia nervosa: an open label trial |
| Q43827163 | Olanzapine in the treatment of anxiety symptoms due to Alzheimer's disease: a post hoc analysis |
| Q42666262 | Olanzapine in the treatment of depression with psychotic features: A prospective open-label study |
| Q34205865 | Olanzapine in the treatment of schizophrenia : an open label comparative clinical trial from north India. |
| Q31440445 | Olanzapine optimal dose: results of an open-label multicenter study in schizophrenic patients. Olanzapine Late-Phase II Study Group |
| Q43845727 | Olanzapine treatment for patients with schizophrenia and substance abuse |
| Q51981823 | Olanzapine versus haloperidol in the treatment of schizophrenia and other psychotic disorders: quality of life and clinical outcomes of a randomized clinical trial. |
| Q53360074 | Olanzapine versus haloperidol: acute phase results of the international double-blind olanzapine trial. |
| Q24236545 | Olanzapine versus other atypical antipsychotics for schizophrenia |
| Q71816819 | Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial |
| Q51969151 | Olanzapine versus risperidone. A prospective comparison of clinical and economic outcomes in schizophrenia. |
| Q44428876 | Olanzapine vs risperidone in the management of schizophrenia: a randomized double-blind trial in Australia and New Zealand |
| Q41348477 | Olanzapine. A review of its pharmacological properties and therapeutic efficacy in the management of schizophrenia and related psychoses |
| Q33747095 | Olanzapine. Pharmacokinetic and pharmacodynamic profile. |
| Q34182274 | Olanzapine: an atypical antipsychotic for schizophrenia |
| Q34669624 | Omega-3 fatty acids in first-episode schizophrenia - a randomized controlled study of efficacy and relapse prevention (OFFER): rationale, design, and methods |
| Q47141676 | One patient with schizophrenia showed reduced drug-induced extrapyramidal symptoms as a result of an alternative regimen of treatment with paliperidone 3 and 6 mg every other day. |
| Q34855041 | Onset of efficacy with acute long-acting injectable paliperidone palmitate treatment in markedly to severely ill patients with schizophrenia: post hoc analysis of a randomized, double-blind clinical trial |
| Q72061655 | Oral administration of NNC 756 — a placebo controlled PET study of D1-dopamine receptor occupancy and pharmacodynamics in man |
| Q24242948 | Oral paliperidone for schizophrenia |
| Q37960632 | Oral ziprasidone in the treatment of patients with bipolar disorders: a critical review |
| Q35636181 | Outcome measures for clinical drug trials in autism |
| Q36417435 | Outcome of Youth with Early-Phase Schizophrenia-Spectrum Disorders and Psychosis Not Otherwise Specified Treated with Second-Generation Antipsychotics: 12 Week Results from a Prospective, Naturalistic Cohort Study |
| Q46472471 | Outcome study of first-episode schizophrenia in a developing country: quality of life and antipsychotics |
| Q74769414 | Overlap between emotional blunting, depression, and extrapyramidal symptoms in schizophrenia |
| Q50776487 | PET analysis of the 5-HT2A receptor inverse agonist ACP-103 in human brain. |
| Q34580449 | Paediatric European Risperidone Studies (PERS): context, rationale, objectives, strategy, and challenges |
| Q48336807 | Paliperidone extended-release as adjunctive therapy to lithium or valproate in the treatment of acute mania: A randomized, placebo-controlled study |
| Q24202846 | Paliperidone palmitate for schizophrenia |
| Q43235031 | Paliperidone palmitate, a potential long-acting treatment for patients with schizophrenia. Results of a randomized, double-blind, placebo-controlled efficacy and safety study |
| Q49996805 | Pathophysiology of drug induced weight and metabolic effects: findings from an RCT in healthy volunteers treated with olanzapine, iloperidone, or placebo. |
| Q37724206 | Patient choice as a driver of medication-switching in non-adherent individuals with bipolar disorder |
| Q34677573 | Patients' subjective experiences of antipsychotics: clinical relevance |
| Q92558889 | Patterns of co-altered brain structure and function underlying neurological soft signs in schizophrenia spectrum disorders |
| Q52105919 | Perseveration and over-switching in schizophrenia |
| Q89351978 | Pharmacokinetic profile after multiple deltoid or gluteal intramuscular injections of paliperidone palmitate in patients with schizophrenia |
| Q39642220 | Pharmacokinetics and Safety Assessment of l-Tetrahydropalmatine in Cocaine Users: A Randomized, Double-Blind, Placebo-Controlled Study |
| Q47814439 | Pharmacokinetics and Safety of Brexpiprazole Following Multiple-Dose Administration to Japanese Patients With Schizophrenia |
| Q48918400 | Pharmacokinetics and central nervous system effects of the novel dopamine D2 receptor antagonist JNJ-37822681. |
| Q50666702 | Pharmacokinetics and central nervous system effects of the novel dopamine D3 receptor antagonist GSK598809 and intravenous alcohol infusion at pseudo-steady state. |
| Q50248080 | Pharmacokinetics and tolerability of paliperidone palmitate injection in Chinese subjects |
| Q68078779 | Pharmacokinetics of raclopride formulations. Influence of prolactin and tolerability in healthy male volunteers |
| Q40720626 | Pharmacokinetics, safety, and tolerability of paliperidone palmitate 3-month formulation in patients with schizophrenia: A phase-1, single-dose, randomized, open-label study |
| Q38220045 | Pharmacological treatment of schizophrenia resistant to first-line treatment: a critical systematic review and meta-analysis |
| Q47319403 | Physical Health and Drug Safety in Individuals with Schizophrenia. |
| Q25257911 | Physical anhedonia in the acute phase of schizophrenia |
| Q51666168 | Placebo response in refractory tardive akathisia. |
| Q35641684 | Placebo-controlled trial of valproic Acid versus risperidone in children 3-7 years of age with bipolar I disorder |
| Q38955072 | Plasma levels and estimated dopamine D2 receptor occupancy of long-acting injectable risperidone during maintenance treatment of schizophrenia: a 3-year follow-up study |
| Q37687951 | Pomaglumetad Methionil (LY2140023 Monohydrate) and Aripiprazole in Patients with Schizophrenia: A Phase 3, Multicenter, Double-Blind Comparison |
| Q48216057 | Positive correlation between reduction of handwriting area and D2 dopamine receptor occupancy during treatment with neuroleptic drugs |
| Q36242623 | Positron emission tomography experience with 2-[¹⁸F]fluoro-3-(2(S)-azetidinylmethoxy)pyridine (2-[¹⁸F]FA) in the living human brain of smokers with paranoid schizophrenia |
| Q89699954 | Post hoc analysis of a randomised, placebo-controlled, active-reference 6-week study of brexpiprazole in acute schizophrenia |
| Q86994144 | Postural control in restless legs syndrome with medication intervention using pramipexole |
| Q42651534 | Potential effectiveness and safety of olanzapine in refractory panic disorder |
| Q92102152 | Practical Guidance on the Use of Lurasidone for the Treatment of Adults with Schizophrenia |
| Q37908140 | Practical guidance for prescribing ziprasidone in acute manic or mixed episodes of bipolar I disorder |
| Q58098576 | Predicting first-episode psychosis patients who will never relapse over 10 years |
| Q42650185 | Predictive Motor Timing and the Cerebellar Vermis in Schizophrenia: An fMRI Study. |
| Q36795862 | Predictive models to estimate utility from clinical questionnaires in schizophrenia: findings from EuroSC. |
| Q37212114 | Predictors of antipsychotic dose changes in the CATIE schizophrenia trial |
| Q52017906 | Predictors of compliance with neuroleptic medication among inpatients with schizophrenia: a discriminant function analysis. |
| Q43161912 | Predictors of early worsening after switch to aripiprazole: a randomized, controlled, open-label study |
| Q74252882 | Predictors of noncompliance in males with first-episode schizophrenia, schizophreniform and schizoaffective disorder |
| Q33709704 | Predictors of switching antipsychotic medications in the treatment of schizophrenia |
| Q37280384 | Preferential binding to dopamine D3 over D2 receptors by cariprazine in patients with schizophrenia using PET with the D3/D2 receptor ligand [(11)C]-(+)-PHNO |
| Q44409504 | Pregabalin-induced akathisia |
| Q33835596 | Preliminary and ongoing French multicenter prospective naturalistic study of adverse events of antipsychotic treatment in naive children and adolescents. |
| Q64770090 | Prevalence and characteristics of patients with pseudoakathisia |
| Q35092839 | Prevalence and correlates of cigarette smoking among Chinese schizophrenia inpatients receiving antipsychotic mono-therapy |
| Q37059217 | Prevalence and correlates of insomnia and its impact on quality of life in Chinese schizophrenia patients |
| Q47627363 | Prevalence and pattern of antipsychotic induced movement disorders in a tertiary care teaching hospital in India - a cross-sectional study. |
| Q83223554 | Prevalence of movement disorders in adolescent patients with schizophrenia and in relationship to predominantly atypical antipsychotic treatment |
| Q40792368 | Prevalence of neuroleptic-induced movement disorders: an 8-year follow-up study in chronic schizophrenia inpatients |
| Q48519491 | Procedural learning in schizophrenia: a functional magnetic resonance imaging investigation |
| Q44784244 | Prolactinemia is uncoupled from central D2/D3 dopamine receptor occupancy in amisulpride treated patients |
| Q36463532 | Prolonged Drug-Drug Interaction between Terbinafine and Perphenazine |
| Q28240120 | Proof-of-concept trial with the neurosteroid pregnenolone targeting cognitive and negative symptoms in schizophrenia |
| Q34032665 | Prospective trial of customized adherence enhancement plus long-acting injectable antipsychotic medication in homeless or recently homeless individuals with schizophrenia or schizoaffective disorder |
| Q46840294 | Proton magnetic resonance spectroscopy during initial treatment with antipsychotic medication in schizophrenia |
| Q94464218 | Proxy WHO Disability Assessment Schedule 2.0 Is Clinically Useful for Assessing Psychosocial Functioning in Severe Mental Illness |
| Q33824032 | Pseudoakathisia: a review and two case reports |
| Q34303518 | Psychometric properties of the Treatment-Emergent Activation and Suicidality Assessment Profile (TEASAP) in youth with OCD |
| Q34157106 | Psychometric properties of the self-report version of the Quick Inventory of Depressive Symptoms (QIDS-SR₁₆) questionnaire in patients with schizophrenia |
| Q39586408 | Psychosis Incident Cohort Outcome Study (PICOS). A multisite study of clinical, social and biological characteristics, patterns of care and predictors of outcome in first-episode psychosis. Background, methodology and overview of the patient sample |
| Q50689567 | Quality of life and treatment costs in schizophrenic outpatients, treated with depot neuroleptics. |
| Q34542824 | Quality of life is predictive of relapse in schizophrenia |
| Q50902652 | Quality of life of Chinese schizophrenia outpatients in Hong Kong: relationship to sociodemographic factors and symptomatology. |
| Q35819467 | Quantifying clinical relevance in the treatment of schizophrenia |
| Q36460702 | Quantitative analysis of motor disturbances in schizophrenic patients. |
| Q42644398 | Quetiapine augmentation of paroxetine CR for the treatment of refractory generalized anxiety disorder: preliminary findings. |
| Q24247154 | Quetiapine for schizophrenia |
| Q30867916 | Quetiapine for schizophrenia. |
| Q31127921 | Quetiapine for the treatment of bipolar II depression: analysis of data from two randomized, double-blind, placebo-controlled studies |
| Q34424124 | Quetiapine fumarate augmentation for patients with a primary anxiety disorder or a mood disorder: a pilot study |
| Q50927580 | Quetiapine in anorexia nervosa patients: an open label outpatient pilot study. |
| Q45093849 | Quetiapine in hospitalized patients with schizophrenia refractory to treatment with first-generation antipsychotics: a 4-week, flexible-dose, single-blind, exploratory, pilot trial |
| Q34965927 | Quetiapine in the treatment of schizophrenia and related disorders |
| Q34486230 | Quetiapine versus aripiprazole in children and adolescents with psychosis--protocol for the randomised, blinded clinical Tolerability and Efficacy of Antipsychotics (TEA) trial |
| Q48496895 | Quetiapine versus olanzapine for the treatment of negative symptoms in patients with schizophrenia |
| Q24202427 | Quetiapine versus other atypical antipsychotics for schizophrenia |
| Q24240989 | Quetiapine versus other atypical antipsychotics for schizophrenia |
| Q91973091 | Randomized Controlled Trial of Paliperidone Extended Release Versus Risperidone for the Treatment of Methamphetamine-Associated Psychosis in Chinese Patients |
| Q86494825 | Randomized controlled study of the T-type calcium channel antagonist MK-8998 for the treatment of acute psychosis in patients with schizophrenia |
| Q92778632 | Randomized controlled trial of a gluten-free diet in patients with schizophrenia positive for antigliadin antibodies (AGA IgG): a pilot feasibility study |
| Q40568751 | Randomized trial of olanzapine versus placebo in the symptomatic acute treatment of the schizophrenic prodrome |
| Q44654540 | Randomized, controlled, double-blind, multicenter comparison of the cognitive effects of ziprasidone versus olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder |
| Q92046656 | Randomized, double-blind, placebo-controlled study of F17464, a preferential D3 antagonist, in the treatment of acute exacerbation of schizophrenia |
| Q59326891 | Rapid agitation control with ketamine in the emergency department (RACKED): a randomized controlled trial protocol |
| Q35738987 | Rasagiline in the Treatment of the Persistent Negative Symptoms of Schizophrenia |
| Q94379686 | Rating Scales and Safety Measurements in Bipolar Disorder and Schizophrenia - A Reference Guide |
| Q55283577 | Rating Scales for Movement Disorders With Sleep Disturbances: A Narrative Review. |
| Q38544223 | Rating scales to measure side effects of antipsychotic medication: A systematic review |
| Q57200375 | Real-world use of quetiapine in early psychosis: An acute inpatient and community follow-up effectiveness study |
| Q44111877 | Reduced directed forgetting for negative words suggests schizophrenia-related disinhibition of emotional cues |
| Q47266542 | Reducing antipsychotic-induced weight gain in schizophrenia: a double-blind placebo-controlled study of reboxetine-betahistine combination |
| Q33818732 | Relapse according to antipsychotic treatment in schizophrenic patients: a propensity-adjusted analysis |
| Q40791623 | Relating Spontaneously Reported Extrapyramidal Adverse Events to Movement Disorder Rating Scales |
| Q44580793 | Relations between movement disorders and psychopathology under predominantly atypical antipsychotic treatment in adolescent patients with schizophrenia |
| Q39829490 | Relationship Between Subjective Experiences and Psychopathological Dimensions in Schizophrenia |
| Q57602651 | Relationship between CYP2D6 genotype and haloperidol pharmacokinetics and extrapyramidal symptoms in healthy volunteers |
| Q44112135 | Relationship between adverse effects of antipsychotic treatment and dopamine D(2) receptor polymorphisms in patients with schizophrenia |
| Q67209926 | Relationship between negative symptoms in chronic schizophrenia and neuroleptic dose, plasma levels and side effects. |
| Q88043671 | Relationship between the plasma concentration of paliperidone and the clinical and drug-induced extrapyramidal symptoms in elderly patients with schizophrenia |
| Q43733972 | Remission in schizophrenia: 196-week, double-blind treatment with ziprasidone vs. haloperidol |
| Q40585989 | Research diagnostic criteria for drug-induced akathisia: conceptualization, rationale and proposal |
| Q50301292 | Response to second generation antipsychotics in youth with comorbid bipolar disorder and autism spectrum disorder. |
| Q44511356 | Restless legs syndrome and drug-induced akathisia in headache patients. |
| Q46533500 | Restless legs syndrome and periodic limb movements during sleep probably associated with olanzapine |
| Q32111784 | Restlessness in suboccipital muscles as a manifestation of akathisia |
| Q27008464 | Review of depot aripiprazole for schizophrenia |
| Q49460831 | Revisiting Antipsychotic-induced Akathisia: Current Issues and Prospective Challenges |
| Q90236876 | Revisiting the Concept of Subjective Tolerability to Antipsychotic Medications in Schizophrenia and its Clinical and Research Implications: 30 Years Later |
| Q38687222 | Risk Factors for Tremor in a Population of Patients with Severe Mental Illness: An 18-year Prospective Study in a Geographically Representative Sample (The Curacao Extrapyramidal Syndromes Study XI). |
| Q43499365 | Risk factors, pre-morbid functioning and episode correlates of neurological soft signs in drug-naive patients with schizophrenia-spectrum disorders. |
| Q33785717 | Risk-Conferring Glutamatergic Genes and Brain Glutamate Plus Glutamine in Schizophrenia |
| Q24185901 | Risperidone (depot) for schizophrenia |
| Q50303584 | Risperidone dosing in children and adolescents with autistic disorder: a double-blind, placebo-controlled study. |
| Q57689372 | Risperidone for psychosis-induced aggression or agitation (rapid tranquillisation) |
| Q42691780 | Risperidone in chronic schizophrenia: a detailed audit, open switch study and two-year follow-up of patients on depot medication |
| Q37803220 | Risperidone long-acting injectable (Risperdal Consta®) for maintenance treatment in patients with bipolar disorder |
| Q45163701 | Risperidone plasma levels, clinical response and side-effects |
| Q80339322 | Risperidone versus Conventional Antipsychotics for Schizophrenia and Schizoaffective Disorder : Symptoms, Quality of Life and Resource Use under Customary Clinical Care |
| Q47681492 | Risperidone versus olanzapine among patients with schizophrenia participating in supported employment: Eighteen-month outcomes |
| Q24244248 | Risperidone versus olanzapine for schizophrenia |
| Q24246232 | Risperidone versus olanzapine for schizophrenia |
| Q47553353 | Risperidone versus other antipsychotics for people with severe mental illness and co-occurring substance misuse. |
| Q24234950 | Risperidone versus other atypical antipsychotics for schizophrenia |
| Q24241041 | Risperidone versus placebo for schizophrenia |
| Q55894951 | Risperidone versus placebo for schizophrenia |
| Q36556433 | Risperidone-associated adverse drug reactions and CYP2D6 polymorphisms in a South African cohort |
| Q34011540 | Role of mirtazapine in the treatment of antipsychotic-induced akathisia |
| Q34184199 | Role of paliperidone extended-release in treatment of schizoaffective disorder |
| Q37495004 | SMARTS (Systematic Monitoring of Adverse events Related to TreatmentS): The development of a pragmatic patient-completed checklist to assess antipsychotic drug side effects. |
| Q100736090 | Safety and Effectiveness of Lurasidone in Adolescents with Schizophrenia: Results of a 2-Year, Open-Label Extension Study |
| Q33587032 | Safety and Tolerability of Adjunctive Aripiprazole in Major Depressive Disorder: A Pooled Post Hoc Analysis (studies CN138-139 and CN138-163). |
| Q50779681 | Safety and efficacy of olanzapine monotherapy in treatment-resistant bipolar mania: a 12-week open-label study. |
| Q41283940 | Safety and efficacy of paliperidone palmitate 1-month formulation in Chinese patients with schizophrenia: a 25-week, open-label, multicenter, Phase IV study |
| Q35062673 | Safety and tolerability of aripiprazole in the treatment of irritability associated with autistic disorder in pediatric subjects (6-17 years old):results from a pooled analysis of 2 studies |
| Q38686408 | Safety and tolerability of cariprazine in patients with acute exacerbation of schizophrenia: a pooled analysis of four phase II/III randomized, double-blind, placebo-controlled studies |
| Q38997108 | Safety and tolerability of cariprazine in the long-term treatment of schizophrenia: results from a 48-week, single-arm, open-label extension study |
| Q45062996 | Safety of Converting From Tetrabenazine to Deutetrabenazine for the Treatment of Chorea |
| Q48651618 | Safety of quetiapine fumarate extended release in the treatment of Korean patients with acute schizophrenia |
| Q37187450 | Safety, tolerability, and efficacy of quetiapine in youth with schizophrenia or bipolar I disorder: a 26-week, open-label, continuation study |
| Q37124457 | Schizophrenia Spectrum Disorders Show Reduced Specificity and Less Positive Events in Mental Time Travel. |
| Q73816004 | Second-generation antipsychotics in the emergency care setting. A prospective naturalistic study |
| Q50479302 | Secondary nonmotor negative symptoms in healthy volunteers after single doses of haloperidol and risperidone: a double-blind, crossover, placebo-controlled trial. |
| Q48571396 | Selective D1- and D2-dopamine receptor blockade both induces akathisia in humans--a PET study with [11C]SCH 23390 and [11C]raclopride |
| Q47552058 | Selective noradrenaline reuptake inhibitors for schizophrenia. |
| Q44628316 | Serotonin transporter polymorphisms and adverse effects with fluoxetine treatment |
| Q24246531 | Sertindole for schizophrenia |
| Q24241594 | Sertindole versus other atypical antipsychotics for schizophrenia |
| Q34737763 | Sertraline and akathisia: spontaneous resolution |
| Q37061289 | Serum Ferritin, Weight Gain, Disruptive Behavior, and Extrapyramidal Symptoms in Risperidone-Treated Youth |
| Q55036456 | Serum iron levels in schizophrenic patients with or without akathisia. |
| Q36949869 | Severely Aggressive Children Receiving Stimulant Medication Versus Stimulant and Risperidone: 12-Month Follow-Up of the TOSCA Trial. |
| Q33799120 | Severity of psychotic episodes in predicting concurrent depressive and anxiety features in acute phase schizophrenia |
| Q37224571 | Sexual dysfunction in patients with schizophrenia treated with conventional antipsychotics or risperidone |
| Q36882931 | Sexual function and gonadal hormones in patients taking antipsychotic treatment for schizophrenia or schizoaffective disorder. |
| Q36324327 | Simvastatin augmentation for recent-onset psychotic disorder: A study protocol |
| Q41614070 | Single- and multiple-dose pharmacokinetics of ziprasidone under non-fasting conditions in healthy male volunteers |
| Q50935734 | Smoking and schizophrenia: is symptom profile related to smoking and which antipsychotic medication is of benefit in reducing cigarette use? |
| Q37322658 | Spontaneous movement disorders in antipsychotic-naive patients with first-episode psychoses: a systematic review |
| Q34048566 | Spontaneous parkinsonism is associated with cognitive impairment in antipsychotic-naive patients with first-episode psychosis: a 6-month follow-up study |
| Q89483192 | Stepped Treatment for Attention-Deficit/Hyperactivity Disorder and Aggressive Behavior: A Randomized, Controlled Trial of Adjunctive Risperidone, Divalproex Sodium, or Placebo After Stimulant Medication Optimization |
| Q48858373 | Striatal dopamine-2 receptor occupancy in psychotic patients treated with risperidone |
| Q48381678 | Striatal vs extrastriatal dopamine D2 receptors in antipsychotic response--a double-blind PET study in schizophrenia |
| Q40785263 | Structured relaxation in the treatment of akathisia: case series |
| Q44374816 | Subchronic haloperidol downregulates dopamine synthesis capacity in the brain of schizophrenic patients in vivo |
| Q37357277 | Subjective Well-Being Under Neuroleptics Scale short form (SWN-K): reliability and validity in an Estonian speaking sample |
| Q53168195 | Subjective quality of life in outpatients with schizophrenia in Hong Kong and Beijing: relationship to socio-demographic and clinical factors. |
| Q51937552 | Suicidal ideation in inpatients with acute schizophrenia. |
| Q34564212 | Sustaining remission of psychotic depression: rationale, design and methodology of STOP-PD II |
| Q46727324 | Switching among antipsychotics in everyday clinical practice: focus on ziprasidone |
| Q33625345 | Switching from Inadequate Adjunctive or Combination Treatment Options to Brexpiprazole Adjunctive to Antidepressant: An Open-Label Study on the Effects on Depressive Symptoms and Cognitive and Physical Functioning. |
| Q33186211 | Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study |
| Q94547427 | Switching to Lurasidone following 12 months of treatment with Risperidone: results of a 6-month, open-label study |
| Q42050098 | Switching to olanzapine long-acting injection from either oral olanzapine or any other antipsychotic: comparative post hoc analyses |
| Q48374043 | Tardive dyskinesia and serum iron indices |
| Q79073519 | Tardive dyskinesia in Chinese inpatients with chronic schizophrenia |
| Q50983184 | Tardive dystonia. Prevalence, risk factors and clinical features. |
| Q33184258 | Temporal modulation of cerebral hemodynamics under prefrontal challenge in schizophrenia: a transcranial Doppler sonography study |
| Q33519733 | Tetrabenazine as anti-chorea therapy in Huntington disease: an open-label continuation study. Huntington Study Group/TETRA-HD Investigators |
| Q52318330 | The Assessment and Treatment of Antipsychotic-Induced Akathisia. |
| Q44778403 | The BTBD9 gene may be associated with antipsychotic-induced restless legs syndrome in schizophrenia. |
| Q33975805 | The Barnes Akathisia Rating Scale--revisited |
| Q51926139 | The European Schizophrenia Cohort (EuroSC): a naturalistic prognostic and economic study. |
| Q47674375 | The Greek version of the calgary depression scale for schizophrenia. |
| Q43623028 | The Hillside Akathisia Scale: a reliability comparison of the English and German versions |
| Q30646868 | The MCIC collection: a shared repository of multi-modal, multi-site brain image data from a clinical investigation of schizophrenia |
| Q41788956 | The Nithsdale schizophrenia surveys. An overview |
| Q29542112 | The PRIME North America randomized double-blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis |
| Q38979325 | The SWITCH study: rationale and design of the trial. |
| Q47762658 | The Treatment of Severe Childhood Aggression Study: 12 Weeks of Extended, Blinded Treatment in Clinical Responders |
| Q77318939 | The accuracy of medical record documentation in schizophrenia |
| Q42546433 | The acute and long-term effect of olanzapine compared with placebo and haloperidol on serum prolactin concentrations |
| Q33950877 | The appropriateness of routine medication treatment for schizophrenia. |
| Q35154166 | The benefit of minocycline on negative symptoms in early-phase psychosis in addition to standard care - extent and mechanism (BeneMin): study protocol for a randomised controlled trial |
| Q33364299 | The co-administration of quetiapine or placebo to cognitive-behavior therapy in treatment refractory depression: a preliminary trial |
| Q33743615 | The cross-sectional GRAS sample: a comprehensive phenotypical data collection of schizophrenic patients |
| Q42686193 | The effect of antipsychotic medication on neuromotor abnormalities in neuroleptic-naive nonaffective psychotic patients: a naturalistic study with haloperidol, risperidone, or olanzapine |
| Q41869167 | The effect of atypical antipsychotics on brain N-acetylaspartate levels in antipsychotic-naïve first-episode patients with schizophrenia: a preliminary study |
| Q37309552 | The effect of brexpiprazole in adult outpatients with early-episode schizophrenia: an exploratory study |
| Q50429581 | The effect of simulated auditory hallucinations on daily activities in schizophrenia patients. |
| Q64814755 | The effect of vitamin E addition to acute neuroleptic treatment on the emergence of extrapyramidal side effects in schizophrenic patients: an open label study |
| Q53902861 | The effectiveness of olanzapine in treatment-refractory schizophrenia when patients are nonresponsive to or unable to tolerate clozapine. |
| Q24800019 | The effects of amisulpride on five dimensions of psychopathology in patients with schizophrenia: a prospective open-label study |
| Q51927623 | The effects of antipsychotic treatment on quality of life of schizophrenic patients under naturalistic treatment conditions: an application of random effect regression models and propensity scores in an observational prospective trial. |
| Q88271142 | The effects of cannabidiol (CBD) on cognition and symptoms in outpatients with chronic schizophrenia a randomized placebo controlled trial |
| Q34988703 | The efficacy and safety of blonanserin compared with haloperidol in acute-phase schizophrenia: a randomized, double-blind, placebo-controlled, multicentre study |
| Q38132709 | The efficacy and safety of switching to ziprasidone from olanzapine in patients with bipolar I disorder: an 8-week, multicenter, open-label study |
| Q51318422 | The efficacy and tolerability of cariprazine in acute mania associated with bipolar I disorder: a phase II trial. |
| Q42495794 | The genetics of antipsychotic induced tremors: a genome-wide pathway analysis on the STEP-BD SCP sample |
| Q34831046 | The heterogeneity of antipsychotic response in the treatment of schizophrenia |
| Q44453886 | The impact upon extra-pyramidal side effects, clinical symptoms and quality of life of a switch from conventional to atypical antipsychotics (risperidone or olanzapine) in elderly patients with schizophrenia. |
| Q42618887 | The influence of switching from risperidone to paliperidone on the extrapyramidal symptoms and cognitive function in elderly patients with schizophrenia: a preliminary open-label trial |
| Q57188390 | The inter-relationships of tardive dyskinesia, parkinsonism, akathisia and tardive dystonia: the Curaçao Extrapyramidal Syndromes Study II |
| Q44053152 | The nature and extent of working memory dysfunction in schizophrenia |
| Q43841257 | The pharmacovigilance of olanzapine: results of a post-marketing surveillance study on 8858 patients in England |
| Q38234325 | The quality of reporting of phase II and III trials for new antipsychotics: a systematic review |
| Q43003327 | The relationship between akathisia and subjective tolerability in patients with schizophrenia |
| Q48010897 | The relationship between excitement symptom severity and extrastriatal dopamine D2/3 receptor availability in patients with schizophrenia: a high-resolution PET study with [(18)F]fallypride |
| Q44610485 | The relationship of changes in leptin, neuropeptide Y and reproductive hormones to antipsychotic induced weight gain. |
| Q38610490 | The safety and tolerability of cariprazine in long-term treatment of schizophrenia: a post hoc pooled analysis |
| Q46906540 | The safety, tolerability, and subject-rated effects of acute intranasal cocaine administration during aripiprazole maintenance |
| Q37267889 | The safety, tolerability, and subject-rated effects of acute intranasal cocaine administration during aripiprazole maintenance II: increased aripipirazole dose and maintenance period. |
| Q36470767 | The side effects of antipsychotic drugs and patients' quality of life: patient education and preference assessment with computers and multimedia. |
| Q35595839 | The treatment of severe child aggression (TOSCA) study: Design challenges |
| Q50748895 | The use of Enhancing Quality Use of Medication Self-Reported Questionniare (EQUIM-SRQ) among mental health consumers: a pilot study. |
| Q34531316 | The α7 Nicotinic Agonist ABT-126 in the Treatment of Cognitive Impairment Associated with Schizophrenia in Nonsmokers: Results from a Randomized Controlled Phase 2b Study |
| Q38667647 | Therapeutic D2/3 receptor occupancies and response with low amisulpride blood concentrations in very late-onset schizophrenia-like psychosis (VLOSLP). |
| Q44547177 | Time course of D2-dopamine receptor occupancy examined by PET after single oral doses of haloperidol |
| Q89599689 | To continue or not to continue? Antipsychotic medication maintenance versus dose-reduction/discontinuation in first episode psychosis: HAMLETT, a pragmatic multicenter single-blind randomized controlled trial |
| Q51877488 | Tolerability of antipsychotic drugs: does patient perspective deserve consideration? |
| Q58715936 | Translation and cultural adaptation of Glasgow Antipsychotic Side-effects Scale (GASS) in Arabic |
| Q34966395 | Treating symptomatic hyperprolactinemia in women with schizophrenia: presentation of the ongoing DAAMSEL clinical trial (Dopamine partial Agonist, Aripiprazole, for the Management of Symptomatic ELevated prolactin). |
| Q40906666 | Treatment adherence in schizophrenia: a patient-level meta-analysis of combined CATIE and EUFEST studies |
| Q34994489 | Treatment of cognitive dysfunction in chronic schizophrenia by augmentation of atypical antipsychotics with buspirone, a partial 5-HT(1A) receptor agonist. |
| Q87278027 | Treatment of first-episode non-affective psychosis: a randomized comparison of aripiprazole, quetiapine and ziprasidone over 1 year |
| Q44357531 | Treatment of weight gain with fluoxetine in olanzapine-treated schizophrenic outpatients |
| Q37302639 | Treatment outcomes of patients with tardive dyskinesia and chronic schizophrenia. |
| Q38056901 | Treatment recommendations for extrapyramidal side effects associated with second-generation antipsychotic use in children and youth. |
| Q46674415 | Treatment response to olanzapine and haloperidol and its association with dopamine D receptor occupancy in first-episode psychosis |
| Q48131663 | Two Phase III randomised double-blind studies of fixed-dose TC-5214 (dexmecamylamine) adjunct to ongoing antidepressant therapy in patients with major depressive disorder and an inadequate response to prior antidepressant therapy |
| Q51782392 | Two subgroups of schizophrenia identified by systematic cognitive neuropsychiatric mapping. |
| Q40036273 | Unusual morphology of scapulae: incidence and dimensions of ossified ligaments and supraspinous bony tunnels for clinical consideration. |
| Q33765226 | Use of intramuscular ziprasidone for the control of acute psychosis or agitation in an inpatient geriatric population: an open-label study. |
| Q24805472 | Validity of Simpson-Angus Scale (SAS) in a naturalistic schizophrenia population |
| Q34988776 | Validity of subjective versus objective quality of life assessment in people with schizophrenia |
| Q22252976 | Valproate for acute mood episodes in bipolar disorder |
| Q33923488 | Varieties of repetitive behavior in autism: comparisons to mental retardation |
| Q47555034 | Vitamin E for antipsychotic-induced tardive dyskinesia |
| Q46908179 | Weight loss in overweight patients maintained on atypical antipsychotic agents |
| Q37699333 | What does risperidone add to parent training and stimulant for severe aggression in child attention-deficit/hyperactivity disorder? |
| Q37300003 | Which rating scales are regarded as 'the standard' in clinical trials for schizophrenia? A critical review. |
| Q35030155 | Within-drug benefit-risk evaluation of olanzapine long-acting injection at one and two years of treatment |
| Q24235066 | Ziprasidone alone or in combination for acute mania |
| Q24242256 | Ziprasidone alone or in combination for acute mania |
| Q30868078 | Ziprasidone for schizophrenia and severe mental illness |
| Q37244876 | Ziprasidone in adolescents with schizophrenia: results from a placebo-controlled efficacy and long-term open-extension study |
| Q24240260 | Ziprasidone versus other atypical antipsychotics for schizophrenia |
| Q34604314 | Ziprasidone vs olanzapine in recent-onset schizophrenia and schizoaffective disorder: results of an 8-week double-blind randomized controlled trial |
| Q53479237 | [How to evaluate side effects in a clinical trial?] |
| Q52837531 | [Tardive movement disorders with antipsychotics – a case of aripirazole-induced tardive dystonia and review of the literature]. |
| Q57665054 | mGlu2/3 Agonists – a New Approach to the Treatment of Schizophrenia: Results of a Randomized Double-Blind Trial |